Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 23Breast Neoplasms 19Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Triple Negative Breast Neoplasms 8Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Hodgkin Disease 4Breast Neoplasms, Male 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Urinary Bladder Neoplasms 2Recurrence 2Prostatic Neoplasms 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Carcinoma 2Uterine Cervical Neoplasms 1Thrombocytosis 1Stages II-III Breast Cancer 1Spinal Cord Compression 1Rectal Neoplasms 1

Interventions

pembrolizumab 1Sirolimus 1Albumin-Bound Paclitaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Cancers × Albumin-Bound Paclitaxel × Clear all
NCT00337376 2014-01-14

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Yale University

Phase 1 Terminated
23 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡